Skip to main content
. 2017 Aug 24;8(61):103014–103031. doi: 10.18632/oncotarget.20488

Figure 5. Dasatinib-resistant cells are able to utilize both PI3K/AKT and MAPK pathways to survive single agent therapy.

Figure 5

(A) DasRes cell growth was assessed by SRB after treatment with the indicated inhibitors for 72 hours. Three independent biological replicates were performed, and the standard error mean is displayed in the quantification graphs. p-value * = 0.05 – 0.01, φ = 0.01 – 0.001, δ = 0.001 – 0.001, Ψ < 0.0001. (B) Apoptosis was measured after 24 hours of treatment with the indicated inhibitors by caspase 3/7 cleavage using the Caspase-Glo 3/7 kit. Fold changes were calculated by comparing treatments to DMSO. (C-D) BRAF-mutant (C) and RAS-mutant (D) control and DasRes cells were treated with the indicated inhibitors for 7 days, and then released for 7 days to assess colony growth after inhibitor treatment. After 2 weeks, cells were fixed and stained with crystal violet. Fold change was calculated by comparing treatments to DMSO.